Direct effects of FGF21 on glucose uptake in human skeletal muscle: Implications for type 2 diabetes and obesity

Diabetes/Metabolism Research and Reviews

Volumn 27, Issue 3, 2011, Pages 286-297

  Mashili, Fredirick L ^a   Austin, Reginald L ^a   Deshmukh, Atul S ^a   Fritz, Tomas ^a   Caidahl, Kenneth ^a   Bergdahl, Katrin ^a   Zierath, Juleen R ^a   Chibalin, Alexander V ^a   Moller, David E ^b   Kharitonenkov, Alexei ^b   Krook, Anna ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

BMI; FGF21; Glucose uptake; Human skeletal muscle

Indexed keywords

FIBROBLAST GROWTH FACTOR 21; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 4; INSULIN; MESSENGER RNA; PROLACTIN;

ADULT; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; BODY MASS; CELL SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; EXTENSOR DIGITORUM LONGUS MUSCLE; FEMALE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCOGEN SYNTHESIS; HOMEOSTATIC MODEL ASSESSMENT OF INSULIN RESISTANCE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; MOUSE; MYOTUBE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROLACTIN SYNTHESIS; SKELETAL MUSCLE; WAIST CIRCUMFERENCE;

ANIMALS; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; FEMALE; FIBROBLAST GROWTH FACTORS; GLUCOSE; GLUCOSE TRANSPORTER TYPE 1; HUMANS; INSULIN; MALE; MICE; MIDDLE AGED; MUSCLE, SKELETAL; OBESITY; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 79952120254     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.1177     Document Type: Article

References (55)

1. Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 2008; 5: 367-377.
2. Pedersen BK, Febbraio MA. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev 2008; 88: 1379-1406.
3. Nishimura T, Nakatake Y, Konishi M, Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 2000; 1492: 203-206.
4. Coskun T, Bina HA, Schneider MA, et al. FGF21 corrects obesity in mice. Endocrinology 2008; 49: 6018-6027.
5. Kharitonenkov A, Shiyanova TL, Koester A, et al. FGF-21 as a novel metabolic regulator. J Clin Invest 2005; 115: 1627-1635.
6. Rydén M. Fibroblast growth factor 21: an overview from a clinical perspective. Cell Mol Life Sci 2009; 66: 2067-2073.
7. Wente W, Efanov AM, Brenner M, et al. Fibroblast growth factor-21 improves pancreat β-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes 2006; 55: 2470-2478.
8. Kharitonenkov A, Wroblewski VJ, Koester A, et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 2007; 148: 774-781.
9. Gälman C, Lundåsen T, Kharitonenkov A, et al. The circulating metabolic regulator FGF21 is induced by prolonged fasting and ppar alpha activation in man. Cell Metab 2008; 8: 169-174.
10. Christodoulides C, Dyson P, Sprecher D, Tsintzas K, Karpe F. Circulating fibroblast growth factor 21 is induced by peroxisome proliferator-activated receptor agonists but not ketosis in man. J Clin Endocrinol Metab 2009; 94: 3594-3601.
11. Moyers JS, Shiyanova TL, Mehrbod F, et al. Molecular determinants of FGF-21 activity-synergy and cross-talk with PPARgamma signaling. J Cell Physiol 2007; 210: 1-6.
12. Goetz R, Beenken A, Ibrahimi OA, et al. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol 2007; 27: 3417-3428.
13. Mohammadi M, Olsen SK, Ibrahimi OA. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Fact Rev 2005; 16: 107-137.
14. Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M, Ornitz DM. Receptor specificity of the fibroblast growth factor family: the complete mammalian fgf family. J Biol Chem 2006; 281: 15694-15700.
15. Izumiya Y, Bina HA, Ouch N, Akasaki Y, Kharitonenkov A, Walsh K. FGF21 is an Akt-regulated myokine. FEBS Lett 2008; 582: 3805-3810.
16. Hojman P, Pedersen M, Nielsen AR, et al. Fibroblast growth factor-21 is induced in human skeletal muscles by hyperinsulinemia. Diabetes 2009; 58: 2797-2801.
17. Inagaki T, Dutchak P, Zhao G, et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab 2007; 5: 415-425.
18. Li X, Ge H, Weiszmann J, et al. Inhibition of lipolysis may contribute to the acute regulation of plasma FFA and glucose by FGF21 in ob/ob mice. FEBS Lett 2009; 583: 3230-3234.
19. Badman MK, Koester A, Flier JS, Kharitonenkov A, Maratos-Flier E. Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology 2009; 150: 4931-4940.
20. Arner P, Pettersson A, Mitchell PJ, Dunbar JD, Kharitonenkov A, Rydén M. FGF21 attenuates lipolysis in human adipocytes a possible link to improved insulin sensitivity. FEBS Lett 2008; 582: 1725-1730.
21. Al-Khalili L, Krämer D, Wretenberg P, Krook A. Enhanced insulin-mediated ERK1/2 MAPK and Akt/PKB phosphorylation in cultured human myocytes post differentiation. Acta Physiol Scand 2004; 180: 395-403.
22. Al-Khalili L, Bouzakri K, Glund S, Lönnqvist F, Koistinen HA, Krook A. Signalling specificity of interleukin-6 action on glucose and lipid metabolism in skeletal muscle. Mol Endocrinol 2006; 20: 3364-3375.
23. Al-Khalili L, Chibalin AV, Kannisto K, et al. Insulin action in cultured human skeletal muscle cells during differentiation: assessment of cell surface GLUT4 and GLUT1 content. Cell Mol Life Sci 2003; 60: 991-998.
24. Barnes BR, Marklund S, Steiler TL, et al. The 5'-AMP-activated protein kinase γ3 isoform has a key role in carbohydrate and lipid metabolism in glycolytic skeletal muscle. J Biol Chem 2004; 279: 38441-38447.
25. Wallberg-Henriksson H, Zetan N, Henriksson J. Reversibility of decreased insulin-stimulated glucose transport capacity in diabetic muscle with in vitro incubation. Insulin is not required. J Biol Chem 1987; 262: 7665-7671.
26. Eto K, Tumenbayar B, Nagashima S-I, et al. Distinct association of serum FGF21 or adiponectin levels with clinical parameters in patients with type 2 diabetes. Diabetes Res Clin Pract 2010; 89: 52-57.
27. Mraz M, Bartlova M, Lacinova Z, et al. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol 2009; 71: 369-375.
28. Kliewer SA, Mangelsdorf DJ. Fibroblast growth factor 21: from pharmacology to physiology. Am J Clin Nutr 2010; 91: 254S-257S.
29. Kharitonenkov A. FGFs and metabolism. Curr Opin Pharmacol 2009; 9: 805-810.
30. Kharitonenkov A, Shanafelt AB. Fibroblast growth factor-21 as a therapeutic agent for metabolic diseases. BioDrugs 2008; 22: 37-44.
31. Zhang X, Yeung DC, Karpisek M, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008; 57: 1246-1253.
32. Ling L, Gangyi Y, Heu N, Mengliu Y, Hua L, Wenwen C. Plasma FGF-21 levels in type 2 diabetic patients with ketosis. Diabetes Res Clin Pract 2008; 82: 209-213.
33. Li K, Li L, Yang M, Zong H, Liu H, Yang G. Effects of rosiglitazone on fasting plasma fibroblast growth factor-21 levels in patients with type 2 diabetes mellitus. Eur J Endocrinol 2009; 161: 391-395.
34. Li H, Bao Y, Xu A, et al. Serum fibroblast growth factor 21 is associated with adverse lipid profiles and γ-glutamyltransferase but not insulin sensitivity in Chinese subjects. J Clin Endocrinol Metab 2009; 94: 2151-2156.
35. Dostalova I, Kavalkova P, Haluzikova D, et al. Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa. J Clin Endocrinol Metab 2008; 93: 3627-3632.
36. Stevenson EJ, Koncarevic A, Giresi PG, Jackman RW, Kandarian SC. Transcriptional profile of a myotube starvation model of atrophy. J Appl Physiol 2005; 98: 1396-1406.
37. Johnson CL, Weston JY, Chadi SA, et al. Fibroblast growth factor 21 reduces the severity of cerulein-induced pancreatitis in mice. Gastroenterology 2009; 137: 1795-1804.
38. Kurosu H, Choi M, Ogawa Y, et al. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem 2007; 282: 26687-26695.
39. Kurosu H, Kuro-o M. The Klotho gene family as a regulator of endocrine fibroblast growth factors. Mol Cell Endocrinol 2009; 299: 72-78.
40. Ito S, Kinoshita S, Shiraishi N, et al. Molecular cloning and expression analyses of mouse β-klotho, which encodes a novel Klotho family protein. Mech Dev 2000; 98: 115-119.
41. Suzuki M, Uehara Y, Motomura-Matsuzaka K, et al. BetaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol Endocrinol 2008; 22: 1006-1014.
42. Tomiyama K-I, Maeda R, Urakawa I, et al. Relevant use of Klotho in FGF19 subfamily signaling system in vivo. Proc Natl Acad Sci U S A 2010; 107: 1666-1671.
43. Karlsson HK, Zierath JR. Insulin signaling and glucose transport in insulin resistant human skeletal muscle. Cell Biochem Biophys 2007; 48: 103-113.
44. Roach WG, Chavez JA, Mîinea CP, Lienhard GE. Substrate specificity and effect on GLUT4 translocation of the Rab GTPase-activating protein TBC1D1. Biochem J 2007; 403: 353-358.
45. Sano H, Kane S, Sano E, et al. Insulin-stimulated phosphorylation of a rab GTPase-activating protein regulates GLUT4 translocation. J Biol Chem 2003; 278: 14599-14602.
46. Long YC, Zierath JR. AMP-activated protein kinase signaling in metabolic regulation. J Clin Invest 2006; 116: 1776-1783.
47. Handberg A, Kayser L, Hoyer PE, Vinten J. A substantial part of GLUT-1 in crude membranes from muscle originates from perineurial sheaths. Am J Physiol Endocrinol Metab 1992; 262: E721-E727.
48. Marette A, Richardson JM, Ramlal T, et al. Abundance, localization, and insulin-induced translocation of glucose transporters in red and white muscle. Am J Physiol Cell Physiol 1992; 263: C443-C452.
49. Kahn BB, Rossetti L, Lodish HF, Charron MJ. Decreased in vivo glucose uptake but normal expression of GLUT1 and GLUT4 in skeletal muscle of diabetic rats. J Clin Invest 1991; 87: 2197-2206.
50. Lund S, Flyvbjerg A, Holman GD, Larsen FS, Pedersen O, Schmitz O. Comparative effects of IGF-I and insulin on the glucose transporter system in rat muscle. Am J Physiol Endocrinol Metab 1994; 267: E461-E466.
51. Zierath JR, Krook A, Wallberg-Henriksson H. Insulin action and insulin resistance in human skeletal muscle. Diabetologia 2000; 43: 821-835.
52. DeFronzo RA. The triumvirate: β-cell, muscle or liver: a collusion responsible for NIDDM. Diabetes 1988; 37: 667-687.
53. DeFronzo RA, Gunnarsson R, Björkman O, Olsson M, Wahren J. Effects of insulin on peripheral and splanchnic glucose metabolism in non-insulin-dependent (type II) diabetes mellitus. J Clin Invest 1985; 76: 149-155.
54. Jody D, Patricia CC, Gosala SG, et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 2010; 139: 456-463.
55. Berglund ED, Li CY, Bina HA, et al. Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. Endocrinology 2009; 150: 4084-4093.